By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Chevron Says Damage at Wheatstone LNG Will Hamper Restart - 2Blood pressure drug recalled for possible cross-contamination
- 3Ukraine confirms defence and energy ministers at second attempt
- 4Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
- 5Jesse Jackson hospitalized, under observation for a neurodegenerative condition
- Europe could get 42 more days of summer by the year 2100 due to climate change
- Most loved Occasion Dish: What Makes Your Merry Table?
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- 'We are ready': NASA still on track to launch Artemis 2 astronauts to the moon April 1
- How to sound like an astronaut as you follow the first human moon mission in more than half a century
- Public Parks in the USA
- Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
- The 15 Most Rousing TED Chats on Self-awareness
